Treatment Advancements are Improving Survivorship and Prompting Hope
Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that… Continue reading →
This animated video from Doc Mike Evans explains the effects of cancer-related fatigue.
Dr. Evans explains that fatigue is the most common medical issue for cancer patients, ranking higher than pain or depression. He shares that cancer fatigue is very different than the… Continue reading →
BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemia, according to Steven P. Treon, MD, PhD, who added that with 4 agents under examination in the space, selection will depend… Continue reading →
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for the treatment of patients with Waldenström’s… Continue reading →
Waldenström Macroglobulinemia (WM) is a low-grade B-cell lymphoproliferative disorder characterized by bone marrow infiltration with lymphoplasmacytic cells, together with an immunoglobulin M (IgM) monoclonal gammopathy. An estimated 1000–1500 new cases of WM are diagnosed in… Continue reading →
The International Waldenstrom’s Macroglobulinemia Foundation invites you to join us for the second installment in our 2020 IWMF Global Educational Webinar series. Through this free interactive webinar series, you will learn from the best and brightest minds in WM research,… Continue reading →